Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
P-Tau231 As a Diagnostic Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis Publisher



Nabizadeh F1, 2 ; Salehi N3 ; Ramezannezhad E4 ; Sadeghmousavi S5 ; Khalili E6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  2. 2. School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran
  7. 7. Universal Scientific Education and Research Network (USERN), Bandar Abbas, Hormozgan, Iran

Source: Annals of Indian Academy of Neurology Published:2022


Abstract

Objective: Some previous studies have shown that cerebrospinal fluid (CSF) levels of p-tau231 were significantly higher in patients with Alzheimer's disease (AD) compared to that in patients with mild cognitive impairment (MCI) and normal control (NC), whereas some other studies did not. Due to contradictory results, we aimed to conduct a systematic review and meta-analysis study on previous investigations to examine the potential role of CSF p-tau231 as a biomarker of AD and MCI. Method: PubMed, Scopus, and Web of Science were searched in March 2021 for studies on the CSF level of p-tau231 in AD, MCI, and NC. The statistical analysis was performed via standardized mean difference (SMD) methodology with a 95% confidence interval. Results: A total of 10 studies including 1141 subjects were included. The present study showed that CSF level of p-tau231 was significantly higher in AD patients compared to that in MCI patients (SMD = 160.94 [11.11, 310.78], P = 0.04) and NC patients (SMD = 436.21 [164.88, 707.54], P < 0.00). Moreover, comparison of MCI and NC showed a significantly higher level of CSF p-tau231 in MCI compared to NC (SMD = 341.44 [59.73, 623.14], P = 0.02). Conclusion: P-tau231 showed to be a valuable biomarker of discrimination AD, MCI, and NC based on our findings. This meta-analysis showed that the CSF p-tau231 can reliably differentiate AD patients from MCI and NC patients. Furthermore, based on our findings the level of CSF p-tau231 was significantly higher in MCI compared to NC. Therefore, p-tau231 can be added to the list of potential biomarkers for the diagnosis of AD and MCI in further studies. However, further investigations are needed to confirm our findings. © 2022 Annals of Indian Academy of Neurology.
Related Docs
View other Related Docs
1. The Role of Csf Biomarkers in Discriminating Between Cerebral Amyloid Angiopathy and Alzheimer’S Disease Patients: Systematic Review of Clinical Studies, Caspian Journal of Neurological Sciences (2024)
2. Diagnostic Role of Tau Proteins in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Scandinavica (2023)
3. A Systematic Review With Meta-Analysis to Assess Alzheimer's Disease Biomarkers in Adults With or Without Obstructive Sleep Apnoea, International Orthodontics (2023)
4. Csf-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients With Alzheimer's Dementia Spectrum, International Journal of Alzheimer's Disease (2023)
5. Uncovering Cerebral Blood Flow Patterns Corresponding to Amyloid-Beta Accumulations in Patients Across the Alzheimer’S Disease Continuum Using the Arterial Spin Labeling, Neurological Sciences (2025)
6. A Comprehensive Investigation of the Associations Between Tensor-Based Morphometry Indices and Executive Functions, Memory, Language, and Visuospatial Abilities in Patients in the Alzheimer's Disease Continuum, Clinical Neurology and Neurosurgery (2024)
7. Neutrophil to Lymphocyte Ratio in Alzheimer’S Disease: A Systematic Review and Meta-Analysis, PLoS ONE (2024)
8. Effectiveness and Safety of Mlc601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial, Dementia and Geriatric Cognitive Disorders Extra (2015)
Experts (# of related papers)
View all Related Experts
Daryoush Shahbazi-Gahrouei (1)
Iman Mohamadi (1)
Other Related Docs
9. Transfer Learning and Neural Network-Based Approach on Structural Mri Data for Prediction and Classification of Alzheimer’S Disease, Diagnostics (2025)
10. Diagnostic Performance of Mri Radiomics for Classification of Alzheimer's Disease, Mild Cognitive Impairment, and Normal Subjects: A Systematic Review and Meta-Analysis, Aging Clinical and Experimental Research (2023)
11. Which Neuroimaging and Fluid Biomarkers Method Is Better in Theranostic of Alzheimer's Disease? an Umbrella Review, IBRO Neuroscience Reports (2024)